Anbio Biotechnology (“Anbio”), a global leader in diagnostics innovation, announces the launch of its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000, a transformative technology designed to deliver rapid, reliable, and cost-effective diagnostic results. Tailored for diverse clinical settings, this solution addresses the growing demand for streamlined workflows and high-performance testing.
Key Highlights of the Anbio Dry CLIA Solution
- Revolutionary Freeze-Dried Reagents:
Eliminates the need for cold chain logistics, enabling room temperature storage and operation. Reagents remain stable without refrigeration, reducing costs and logistical challenges.
- Advanced Whole Blood Testing:
Incorporates innovative onboard separation technology, directly processing whole blood into plasma for analysis. Results are derived without conversions, ensuring uncompromised accuracy.
- Rapid Emergency Testing Capabilities:
Features a dedicated emergency testing slot for immediate processing. Delivers results for critical assays within 15 minutes, meeting the stringent turnaround time (TAT) requirements of emergency departments.
- Compact and Efficient Design:
With a minimal footprint of 0.518m2, the system is optimized for space-constrained environments. It supports continuous operation with a throughput of 180 tests/hour.
- Minimal Waste with Single-Test Flexibility:
Designed for single-use testing on demand, the system minimizes reagent waste, offering unparalleled operational efficiency.
- Comprehensive Assay Portfolio:
Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer’s disease, thrombosis, and pre-eclampsia. These unique assays expand the scope of diagnostic possibilities, catering to the evolving needs of modern medicine.
“The Anbio Dry CLIA Solution represents a significant advancement in diagnostic technology, offering unparalleled speed and accuracy while addressing the logistical challenges faced by healthcare providers worldwide,”said Michael Lau, CEO at Anbio Biotechnology.
